Navigation Links
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
Date:8/8/2014

SAN DIEGO, Aug. 8, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided an update on its drug development programs.

"In the past quarter we expanded the scope of our clinical programs, identified compelling patient selection strategies targeting driver mutations, and positioned the company to obtain initial data by the end of the year from multiple proof of concept studies," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "We have made significant strides in executing on our precision oncology strategy and are looking forward to achieving significant milestones within each of our programs."

Second Quarter 2014 Business UpdateMGCD265

  • Phase 1 safety and dose escalation study ongoing
  • Planning to initiate expansion cohorts with a goal of obtaining initial proof of concept data by the end of 2014 in patients who have genetic alterations in Met and Axl
  • MGCD516

  • Phase 1 safety and dose escalation study initiated
  • On track to identify a Phase 2 dose by the end of 2014
  • Mocetinostat

  • Secured orphan drug designation for mocetinostat in myelodysplastic syndromes; orphan applications for bladder cancer and diffuse large b-cell lymphoma (DLBCL) have been submitted
  • The mocetinostat Phase 2 dose confirmation trial is ongoing and the mocetinostat Phase 2 trials in bladder cancer and DLBCL will commence in Q3 with the goal of obtaining initial proof of concept data by the end of 2014
  • Second Quarter 2014 Financial Results Cash, cash equivalents, and short-term investments were $47.4 million at June 30, 2014, compared to $62.1 million at December 31, 2013.

    Research and development expenditures for the second quarter of 2014 were $7.2 million, compared to $4.5 million for the same period in 2013. Research and development expenses for the six months ended June 30, 2014 were $12.4 million, compared to $10.0 million for the same period in 2013. The Company's research and development expenses during the second quarter and six months ended June 30, 2014 primarily consisted of costs to advance the clinical development of its three oncology programs, MGCD265, MGCD516 and mocetinostat. General and administrative expenses for the second quarter of 2014 were $2.9 million, compared to $2.4 million for the same period in 2013. General and administrative expenses for the six months ended June 30, 2014 were $5.3 million, compared to $4.9 million for the same period in 2013.

    Other expense, net for the second quarter of 2014 was $0.9 million compared to $1.1 million for the same period in 2013. Other expense, net for the six months ended June 30, 2014 was $6.6 million compared to other income of $2.7 million for the same period in 2013. Other income or expense, net is comprised primarily of gains or losses arising from the change in fair value of our warrant liability.

    Net loss and comprehensive loss for the second quarter was $11.0 million, or $0.82 per share, compared to net loss and comprehensive loss of $8.0 million, or $0.80 per share for the same period in 2013. Net loss and comprehensive loss for the six months ended June 30, 2014 was $24.7 million, or $1.83 per share, compared to net loss and comprehensive loss of $12.2 million, or $1.23 per share for the same period in 2013.

    About Mirati Therapeutics
    Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using a proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bio-available, spectrum-selective histone deacetylase inhibitor. More information is available at www.mirati.com.

    Forward Looking Statements
    Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Mirati and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Mirati's control. Such statements can usually be identified by the use of words such as "may", "would", "believe", "intend", "plan", "anticipate", "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved. Forward-looking statements in this release include, but are not limited to, statements regarding the timing of initiating and reporting data from clinical trials, the potential for MGCD265 to show signals of activity in Met and Axl pathways and the potential for accelerated approval pathways.

    Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Mirati will be able to obtain financing when needed or on favorable terms, and other risks described in Mirati's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Mirati cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Mirati does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.

    Company Contact:
    Mirati Therapeutics Inc.
    Mark J. Gergen
    Executive Vice President & COO
    858-332-3410

    Investor Relations and Media Relations:
    Jason Spark
    Canale Communications
    619-849-6005
    jason@canalecomm.com

     Mirati Therapeutics, Inc.Consolidated Balance Sheets(in thousands)June 30,December 31,20142013Assets(unaudited)  Current assetsCash, cash equivalents and short-term investments$
    47,417
    $
    2,070
    Other current assets1,7442,145Total current assets49,16164,215Other assets24-Property and equipment, net479322Total assets$
    49,664
    $
    4,537
    Liabilities and Stockholders' Equity  Current liabilitiesAccounts payable and accrued liabilities5,9155,245Warrant liability38,92433,407Total liabilities44,83938,652Stockholders' equity4,82525,885Total liabilities and stockholders' equity$
    49,664
    $
    4,537
     Mirati Therapeutics, Inc.Consolidated Statements of Operations and Comprehensive Loss(in thousands except per share data, unaudited)Three months endedSix months endedJune 30,June 30,2014201320142013ExpensesResearch and development$
    7,236
    $
    4,510
    $   12,443$
    9,985
    General and administrative2,8782,3825,2934,906Restructuring costs--334-Total operating expenses10,1146,89218,07014,891Loss from operations(10,114)(6,892)(18,070)(14,891)Other income (expense), net(924)(1,079)(6,624)2,722Loss before income taxes(11,038)(7,971)(24,694)(12,169)Income tax expense-41-60Net loss$(11,038)$  (8,012)$(24,694)$(12,229)Unrealized gain on available-for-sale investments24-34-Comprehensive loss$ (11,014)$  (8,012)$ (24,660)$ (12,229)Basic and diluted net loss per share$
    (0.82)
    $
    (0.80)
    $
    (1.83)
    $
    (1.23)
    Weighted average number of shares used in computing net loss per share, basic and diluted13,4999,95813,4679,958 


    '/>"/>
    SOURCE Mirati Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
    2. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    3. Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
    5. Mirati Therapeutics Prices Public Offering Of Common Stock
    6. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
    7. Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
    8. PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
    9. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
    10. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
    11. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... -- NOIT™ Research LLC, a private, leading-edge autism research group, ... assist needy families in obtaining one of its special ... 10, 2016 and March 31, 2016, the company will ... is an auditory stimulus that plays a key role ... Beth Shier , NOIT Research director. "The ...
    (Date:2/11/2016)... N.C. , Feb. 11, 2016 ... leading provider of custom manufacturing and development services ... expanded sterile fill-finish capabilities and capacity in its ... growth in demand has driven several recent investments. ... 2001 it had one filling line with small-scale ...
    (Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... , ... February 12, 2016 , ... The law firm ... and Evangeline Parishes. The purpose of these scholarships is to encourage applicants to ... individuals to seek employment within these two parishes. , “We have available jobs ...
    (Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
    (Date:2/12/2016)... ... February 12, 2016 , ... ... (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, a ... offer real-time business intelligence (BI) to their small and medium business (SMB) clients. ...
    (Date:2/12/2016)... ... 2016 , ... Vail knee specialist Robert LaPrade, MD, PhD was ... The list consists of physicians establishing, leading and partnering with ambulatory surgery centers across ... Ambulatory Surgery Center, also known as an ASC, is a modern health care facility ...
    (Date:2/12/2016)... ... 2016 , ... For Coast Dental dentist Everet Lake, DDS, the smiles began ... Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event ... skills to help hundreds of uninsured and underinsured people receive much-needed dental care. ...
    Breaking Medicine News(10 mins):